PriceTargets.com logo

NovaBay Pharmaceuticals - NBY Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.69 As of 06/8/2023 01:00 AM ET
▼ -0.02 (-2.82%)

This chart shows the closing price for NBY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NovaBay Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NovaBay Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.69.

This chart shows the closing price for NBY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in NovaBay Pharmaceuticals. This rating has held steady since September 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/20/2022Ascendiant Capital MarketsLower Target$148.75 ➝ $140.00
10/7/2021LADENBURG THALM/SH SHBoost TargetBuy$66.50 ➝ $77.00
9/18/2019LADENBURG THALM/SH SHInitiated CoverageBuy$38.50
3/13/2019HC WainwrightDowngradeBuy ➝ Neutral
3/13/2019LaidlawDowngradeBuy ➝ Hold
1/11/2019HC WainwrightSet TargetBuy$70.00
11/15/2018HC WainwrightSet TargetBuy$105.00
8/8/2018HC WainwrightSet TargetBuy$140.00
7/6/2018HC WainwrightSet TargetBuy$140.00
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/10/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/9/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NovaBay Pharmaceuticals logo
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.
Read More

Today's Range

Now: $0.69
Low: $0.66
High: $0.72

50 Day Range

MA: $1.22
Low: $0.64
High: $1.80

52 Week Range

Now: $0.69
Low: $0.48
High: $12.64

Volume

303,539 shs

Average Volume

290,349 shs

Market Capitalization

$1.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.69

Frequently Asked Questions

What sell-side analysts currently cover shares of NovaBay Pharmaceuticals?

The following sell-side analysts have issued research reports on NovaBay Pharmaceuticals in the last year: StockNews.com.
View the latest analyst ratings for NBY.

What is the current price target for NovaBay Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for NovaBay Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NovaBay Pharmaceuticals in the next year.
View the latest price targets for NBY.

What is the current consensus analyst rating for NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NBY.

What other companies compete with NovaBay Pharmaceuticals?

Other companies that are similar to NovaBay Pharmaceuticals include Achaogen, Sunwin Stevia International, Scopus BioPharma, Altamira Therapeutics and International Stem Cell. Learn More about companies similar to NovaBay Pharmaceuticals.

How do I contact NovaBay Pharmaceuticals' investor relations team?

NovaBay Pharmaceuticals' physical mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company's listed phone number is (510) 899-8800 and its investor relations email address is jcai[email protected]. The official website for NovaBay Pharmaceuticals is novabay.com. Learn More about contacing NovaBay Pharmaceuticals investor relations.